{"id":"W4417008450","doi":"10.1182/blood-2025-885","title":"Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Bendamustine; Hazard ratio; Clinical endpoint; Discontinuation; Rituximab; Randomization; Confidence interval; Phases of clinical research; Mantle cell lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003834836,0.0004621598,0.001648379,0.0002909326,0.0001798619,0.001129741,0.0005647358,0.0006656982,0.0017588],"category_scores_gemma":[0.003502342,0.0002813884,0.002687436,0.0006800797,0.0002045484,0.000935578,0.0004164713,0.001452893,0.000257648],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005277832,"about_ca_system_score_gemma":0.0005965178,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000921295,"about_ca_topic_score_gemma":0.002279073,"domain_scores_codex":[0.9986143,0.0007109944,0.0001155004,0.0002580917,0.0001772264,0.000123847],"domain_scores_gemma":[0.9973263,0.0008303853,0.001049306,0.0003032114,0.0002048059,0.0002859269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7098567,0.001942595,0.165742,0.001764993,0.02564365,0.0001794389,0.000193295,0.003837535,0.005655702,0.0002565974,0.006072533,0.07885493],"study_design_scores_gemma":[0.1542371,0.06686524,0.7271313,0.0003773289,0.03271164,0.0005646416,0.0001291792,0.004611714,0.002452436,0.0007212223,0.0100747,0.0001234156],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816675,0.01098714,0.0006609719,0.0003076202,0.0001067174,0.0002456096,0.004428316,0.00003907071,0.001557165],"genre_scores_gemma":[0.9914154,0.001359528,0.0003532951,0.0003998849,0.0001282571,0.0002904836,0.00542771,0.00001813107,0.0006073389],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003834836,"threshold_uncertainty_score":0.02028078,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006260741455784101,"score_gpt":0.2477104781958943,"score_spread":0.2414497367401102,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}